Genmab A/S Files 6-K on Share Buy-back Program
Ticker: GNMSF · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, disclosure, sec-filing
TL;DR
Genmab files 6-K for share buy-back program updates.
AI Summary
On June 2, 2025, Genmab A/S announced transactions related to its share buy-back program. The company is filing this report on Form 6-K to incorporate by reference into its existing S-8 registration statements.
Why It Matters
This filing provides transparency on Genmab's ongoing share repurchase activities, which can impact share price and investor perception.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share buy-back program transactions and does not introduce new material risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- June 2, 2025 (date) — Announcement Date
- 333-232693 (other) — Form S-8 File Number
- 333-253519 (other) — Form S-8 File Number
- 333-262970 (other) — Form S-8 File Number
- 333-277273 (other) — Form S-8 File Number
- 333-284876 (other) — Form S-8 File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K filing is to report transactions in connection with Genmab A/S's share buy-back program and to be incorporated by reference into its existing registration statements on Form S-8.
What specific exhibit is included with this filing?
Exhibit 99.1 is included, which is a Company Announcement dated June 2, 2025, detailing transactions in connection with the share buy-back program.
Which registration statements will this 6-K filing be incorporated into?
This 6-K filing will be incorporated by reference into Genmab A/S's registration statements on Form S-8 with file numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What is the filing date and period of report for this document?
The filing date and conformed period of report is June 2, 2025.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding GENMAB A/S (GNMSF).